Calithera Biosciences, Inc. (CALA)
OTCMKTS
· Delayed Price · Currency is USD
0.0006
-0.0094 (-94.00%)
Feb 18, 2025, 3:00 PM EST
Calithera Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|
Period Ending | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | - | 9.75 | - | - | 22.25 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -14.26% | Upgrade
|
| Cost of Revenue | 28.53 | 53.46 | 71.02 | 76.29 | 66.2 | Upgrade
|
| Gross Profit | -28.53 | -43.71 | -71.02 | -76.29 | -43.94 | Upgrade
|
| Selling, General & Admin | 13.54 | 20.85 | 20.37 | 16.61 | 13.34 | Upgrade
|
| Research & Development | - | 50.88 | - | - | - | Upgrade
|
| Operating Expenses | 13.54 | 71.73 | 20.37 | 16.61 | 13.34 | Upgrade
|
| Operating Income | -42.07 | -115.43 | -91.39 | -92.9 | -57.28 | Upgrade
|
| Interest Expense | - | -0.02 | - | - | - | Upgrade
|
| Interest & Investment Income | 0.48 | - | 1.25 | 3.04 | 2.65 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.95 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -39.65 | -115.45 | -90.14 | -89.86 | -54.63 | Upgrade
|
| Other Unusual Items | - | 0.36 | - | - | - | Upgrade
|
| Pretax Income | -39.65 | -115.09 | -90.14 | -89.86 | -54.63 | Upgrade
|
| Net Income | -39.65 | -115.09 | -90.14 | -89.86 | -54.63 | Upgrade
|
| Preferred Dividends & Other Adjustments | -18.36 | - | - | - | - | Upgrade
|
| Net Income to Common | -21.29 | -115.09 | -90.14 | -89.86 | -54.63 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 4 | 3 | 2 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 4 | 3 | 2 | 2 | Upgrade
|
| Shares Change (YoY) | 35.17% | 7.32% | 45.46% | 29.25% | 11.09% | Upgrade
|
| EPS (Basic) | -4.60 | -31.16 | -26.20 | -37.99 | -29.85 | Upgrade
|
| EPS (Diluted) | -7.94 | -31.16 | -26.20 | -37.99 | -29.85 | Upgrade
|
| Free Cash Flow | -43.74 | -66.45 | -84.37 | -78.75 | -65.06 | Upgrade
|
| Free Cash Flow Per Share | -8.76 | -17.99 | -24.52 | -33.29 | -35.55 | Upgrade
|
| Gross Margin | - | - | - | - | -197.45% | Upgrade
|
| Operating Margin | - | -1183.93% | - | - | -257.40% | Upgrade
|
| Profit Margin | - | -1180.39% | - | - | -245.48% | Upgrade
|
| Free Cash Flow Margin | - | -681.51% | - | - | -292.33% | Upgrade
|
| EBITDA | -41.82 | -115.15 | -91.02 | -92.42 | -56.78 | Upgrade
|
| EBITDA Margin | - | - | - | - | -255.13% | Upgrade
|
| D&A For EBITDA | 0.26 | 0.28 | 0.36 | 0.48 | 0.51 | Upgrade
|
| EBIT | -42.07 | -115.43 | -91.39 | -92.9 | -57.28 | Upgrade
|
| EBIT Margin | - | - | - | - | -257.40% | Upgrade
|
| Revenue as Reported | - | 9.75 | - | - | 22.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.